

## Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

July 8, 2020

The Manager DCS-LISTING M/s. BSE Ltd Dalal Street,

Phiroze Jeejeebhoy Towers <u>Mumbai 400 001</u>

<u>Scrip Code: **524816**</u>

Manager - Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E)

Mumbai -400 051

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclosed herewith Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended June 30, 2020

Kindly acknowledge receipt of the same.

Thanking you

Yours faithfully For NATCO Pharma Limited

MANarayona

M Adinarayana Company Secretary & Vice President (Legal & Corporate Affairs)

Encl. As Above.





To, Date: 01.07.2020

The Company Secretary, Natco Pharma Limited, Natco House, Road No.2, Banjara Hills, Hyderabad – 500 034

Sub: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30.06.2020

Ref: Security Code - 524816ISIN: INE987B01026

Dear Sir/Madam,

We hereby certify that the securities received for dematerialisation have been mutilated and cancelled after due verification and the name of the depositories (National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) has been updated in the records of company as the registered owner within 15 days of receipt of valid DRF & Share certificate of said company and the details of securities are furnished to the stock exchange(s).

We request you to take this information on record and to inform Depositories(s) and Stock Exchange(s) wherever your securities are listed accordingly.

Thanking you,

Yours faithfully,

For Venture Capital and Corporate Investments Private Limited.



Authorised Signatory.